A New Review Makes the Case for AI in Antiviral Discovery, but Biology Remains the Constraint
A ScienceDirect review examines whether artificial intelligence can transform antiviral drug discovery, framing both the promise and the practical limits of computational approaches in infectious disease. The article is timely as governments and industry continue searching for faster pandemic-response capabilities without overestimating what models can deliver absent strong virology and translational data.
The question of whether AI can transform antiviral drug discovery has renewed urgency in the post-pandemic period, and the new review usefully centers a critical point: infectious disease is not just another optimization problem. Antiviral development depends on fast-moving pathogen biology, resistance patterns, host interactions, and clinical deployment realities that often make the discovery environment far messier than benchmark datasets suggest.
AI can still add real value. It may help identify viral or host targets, propose compounds, predict binding or resistance liabilities, and triage candidates faster than traditional approaches alone. In outbreak settings, the attraction is obvious: compress early discovery timelines and widen the search space when speed matters. But the practical bottlenecks remain experimental validation, assay quality, and the challenge of translating in vitro promise into useful therapeutics under real-world time pressure.
The review’s importance lies in its implicit caution against techno-solutionism. Antiviral R&D is particularly sensitive to data sparsity and shifting biological context. Models trained on historical compounds or known pathogens may be less reliable when confronted with novel viral families or poorly characterized mechanisms. This means preparedness cannot be reduced to having better algorithms; it also requires stronger biological surveillance, standardized datasets, and lab capacity that can rapidly test AI-generated hypotheses.
For healthcare and life sciences leaders, the takeaway is strategic. AI may become an important layer in antiviral readiness, but only if it is embedded into a broader preparedness stack that includes public-health infrastructure, translational science, and manufacturing planning. The biggest gains will likely come from integrated systems that connect computation to experimental and clinical response, not from standalone model performance claims.